Scholar Rock Holding Corp
2QK
Company Profile
Business description
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Contact
301 Binney Street
3rd Floor
CambridgeMA02142
USAT: +1 857 259-3860
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
196
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,144.50 | 8.00 | -0.09% |
| CAC 40 | 7,896.93 | 71.69 | 0.92% |
| DAX 40 | 23,748.86 | 50.71 | 0.21% |
| Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
| FTSE 100 | 9,277.03 | 6.26 | -0.07% |
| HKSE | 26,453.86 | 7.30 | 0.03% |
| NASDAQ | 22,348.75 | 207.64 | 0.94% |
| Nikkei 225 | 44,957.59 | 189.47 | 0.42% |
| NZX 50 Index | 13,211.06 | 2.75 | 0.02% |
| S&P 500 | 6,615.28 | 30.99 | 0.47% |
| S&P/ASX 200 | 8,871.10 | 9.60 | -0.11% |
| SSE Composite Index | 3,859.41 | 1.10 | -0.03% |